Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 14/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18547059 | 0.86 | JAK2 (0.47) | JAK2JAK1TYK2JAK3CNR1 | |
| SCHEMBL18547403 | 0.85 | MCHR1 (0.45) | CNR1MCHR1 | |
| SCHEMBL18575794 | 0.84 | CNR1 (0.48) | CNR1MCHR1 | |
| SCHEMBL18562587 | 0.84 | CNR1 (0.48) | CNR1MCHR1 | |
| Hydrochloric Acid SCHEMBL18546996 | 0.83 | CNR1 (0.47) | CNR1MCHR1 | |
| SCHEMBL18547218 | 0.83 | MCHR1 (0.43) | CNR1MCHR1 | |
| SCHEMBL18547329 | 0.83 | CNR1 (0.43) | CNR1 | |
| SCHEMBL18576135 | 0.83 | MCHR1 (0.43) | CNR1MCHR1 | |
| SCHEMBL18547587 | 0.82 | CNR1 (0.42) | CNR1 | |
| SCHEMBL18562610 | 0.82 | HRH1 (0.50) | MCHR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| WO-2017035114-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | JAK2 966/4885JAK1 1437/4885TYK2 4182/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | JAK2 999/4885JAK1 1481/4885TYK2 4212/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | JAK2 999/4885JAK1 1481/4885TYK2 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.